- Compugen Ltd. announces new research that enables accurate detection and study of the novel target PVRIG following correction of the GENCODE gene model, which could lead to the development of new cancer immunotherapies; there is no clear indication in the article why AstraZeneca (AZN) stock may have gone down.
- The article reports on a range of London-listed shares that received analyst recommendations on Wednesday and Tuesday, with Berenberg cutting AstraZeneca's price target to 12,400 pence from 12,600 pence and therefore, causing the stock (AZN) to fall by 0.78%.
- Silence Therapeutics reported its financial results for Q4 and full year ended December 31, 2022, which showed a net loss after tax of £40.5m ($56m) for the year, mostly attributed to an increase in R&D expenditures to expand the company’s innovative medicines pipeline, and the company held a conference call to discuss these results, causing some investors to sell off shares and causing a slight drop of 0.78% in the AZN stock, which is connected to Silence Therapeutics through a research and development collaboration.
- European banks, including Credit Suisse, UniCredit, Societe Generale, and Monte dei Paschi have come under heightened scrutiny as investors become increasingly concerned that the sector is exposed to the impact of a rapid decrease in government bond values; tightening bank margins. Additionally, CREDIT Suisse stock value plunged by 20% and trading was halted amid market speculation on its financial health.
- Astrazeneca's stock (AZN) went down -0.78% last night, but the article does not provide a reason for the drop as it discusses a new study on a potential treatment for acute leukemia.
- Pancreatic cancer breakthroughs from companies such as Oncolytics Biotech Inc., Biomea Fusion, Inc., AIM ImmunoTech Inc., AstraZeneca PLC, and Novartis AG are creating optimism for 2023, however, there is no clear indication why AstraZeneca's stock went down 0.14% last night.
- The article discusses the developments in pancreatic cancer treatment by various biotech companies, including AstraZeneca, but does not provide any specific reason for the company's stock going down by 0.14% last night.
- Prenetics, a leading genomics and precision oncology company, announced its financial results for the fourth quarter and full year ended December 31, 2022, with a new business strategy focused on precision oncology, leading to a workforce reduction of approximately 60% and selling off its COVID-19 testing business, causing a decrease in stock value for AstraZeneca.
- Prenetics Global Limited, a leading genomics and precision oncology company, announced financial results for Q4 and FY2022, and its focus on a new business strategy in precision oncology, causing investor concerns and a drop in the AstraZeneca (AZN) stock, which Prenetics has recently acquired.
- The stock of biotech giant Amgen (AMGN) declined due to declining sales of some of its key products, while online dating specialist Match Group (MTCH) is facing multiple near-term issues, including low or declining revenue growth and a drop in the number of paying subscribers. However, both companies have excellent prospects with Amgen launching new products and acquiring promising clinical compounds, and Match Group's Tinder platform continuing to dominate the online dating market with opportunities for growth in untapped markets such as Asia.